Transcode Therapeutics, Inc. - 8-K Filing
Transcode Therapeutics received a Nasdaq deficiency letter on May 19, 2026, for failing to meet the minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1). The company reported stockholders' equity of $1.25 million as of March 31, 2026. It has until July 3, 2026 to submit a plan for compliance and may receive an extension up to 180 days.
Tickers: $RNAZ